AAV-based gene therapy products utilize adeno-associated virus (AAV) vectors as delivery vehicles to transfer therapeutic genes into target cells for the treatment of various genetic disorders and diseases. AAV vectors are non-pathogenic viruses that can efficiently infect a wide range of cells and have a low immunogenicity profile, making them suitable candidates for gene therapy applications. In AAV-based gene therapy, the therapeutic gene of interest is inserted into the AAV vector's genome, and the vector is then administered to the patient, typically via intravenous injection or direct injection into the affected tissue. Once inside the target cells, the AAV vector delivers the therapeutic gene, allowing it to be expressed and produce the desired therapeutic protein. AAV-based gene therapy products hold significant promise for the treatment of inherited genetic disorders, as well as acquired diseases such as certain types of cancer and neurodegenerative disorders, offering potential long-term therapeutic benefits with a single administration.
The global AAV-based Gene Therapy Products market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “AAV-based Gene Therapy Products Industry Forecast” looks at past sales and reviews total world AAV-based Gene Therapy Products sales in 2023, providing a comprehensive analysis by region and market sector of projected AAV-based Gene Therapy Products sales for 2024 through 2030. With AAV-based Gene Therapy Products sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world AAV-based Gene Therapy Products industry.
This Insight Report provides a comprehensive analysis of the global AAV-based Gene Therapy Products landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on AAV-based Gene Therapy Products portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global AAV-based Gene Therapy Products market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for AAV-based Gene Therapy Products and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global AAV-based Gene Therapy Products.
United States market for AAV-based Gene Therapy Products is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for AAV-based Gene Therapy Products is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for AAV-based Gene Therapy Products is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key AAV-based Gene Therapy Products players cover uniQure, Spark Therapeutics, AveXis (Novartis), PTC Therapeutics, BioMarin, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of AAV-based Gene Therapy Products market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
AAV2
AAV8
AAV9
Others
Segmentation by Application:
Haematology
Ophthalmology
Neurology
Musculoskeletal
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
uniQure
Spark Therapeutics
AveXis (Novartis)
PTC Therapeutics
BioMarin
Sarepta Therapeutics
Roche
Pfizer
CSL Behring
Sangamo Therapeutics
Biogen
Freeline Therapeutics
Coave Therapeutics
MeiraGTx
RegenxBio
Asklepios Biopharmaceutical
Audentes Therapeutics
Neurophth
Belief BioMed
Key Questions Addressed in this Report
What is the 10-year outlook for the global AAV-based Gene Therapy Products market?
What factors are driving AAV-based Gene Therapy Products market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do AAV-based Gene Therapy Products market opportunities vary by end market size?
How does AAV-based Gene Therapy Products break out by Type, by Application?

1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global AAV-based Gene Therapy Products Annual Sales 2019-2030 2.1.2 World Current & Future Analysis for AAV-based Gene Therapy Products by Geographic Region, 2019, 2023 & 2030 2.1.3 World Current & Future Analysis for AAV-based Gene Therapy Products by Country/Region, 2019, 2023 & 2030 2.2 AAV-based Gene Therapy Products Segment by Type 2.2.1 AAV2 2.2.2 AAV8 2.2.3 AAV9 2.2.4 Others 2.3 AAV-based Gene Therapy Products Sales by Type 2.3.1 Global AAV-based Gene Therapy Products Sales Market Share by Type (2019-2024) 2.3.2 Global AAV-based Gene Therapy Products Revenue and Market Share by Type (2019-2024) 2.3.3 Global AAV-based Gene Therapy Products Sale Price by Type (2019-2024) 2.4 AAV-based Gene Therapy Products Segment by Application 2.4.1 Haematology 2.4.2 Ophthalmology 2.4.3 Neurology 2.4.4 Musculoskeletal 2.4.5 Others 2.5 AAV-based Gene Therapy Products Sales by Application 2.5.1 Global AAV-based Gene Therapy Products Sale Market Share by Application (2019-2024) 2.5.2 Global AAV-based Gene Therapy Products Revenue and Market Share by Application (2019-2024) 2.5.3 Global AAV-based Gene Therapy Products Sale Price by Application (2019-2024) 3 Global by Company 3.1 Global AAV-based Gene Therapy Products Breakdown Data by Company 3.1.1 Global AAV-based Gene Therapy Products Annual Sales by Company (2019-2024) 3.1.2 Global AAV-based Gene Therapy Products Sales Market Share by Company (2019-2024) 3.2 Global AAV-based Gene Therapy Products Annual Revenue by Company (2019-2024) 3.2.1 Global AAV-based Gene Therapy Products Revenue by Company (2019-2024) 3.2.2 Global AAV-based Gene Therapy Products Revenue Market Share by Company (2019-2024) 3.3 Global AAV-based Gene Therapy Products Sale Price by Company 3.4 Key Manufacturers AAV-based Gene Therapy Products Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers AAV-based Gene Therapy Products Product Location Distribution 3.4.2 Players AAV-based Gene Therapy Products Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024) 3.6 New Products and Potential Entrants 3.7 Market M&A Activity & Strategy 4 World Historic Review for AAV-based Gene Therapy Products by Geographic Region 4.1 World Historic AAV-based Gene Therapy Products Market Size by Geographic Region (2019-2024) 4.1.1 Global AAV-based Gene Therapy Products Annual Sales by Geographic Region (2019-2024) 4.1.2 Global AAV-based Gene Therapy Products Annual Revenue by Geographic Region (2019-2024) 4.2 World Historic AAV-based Gene Therapy Products Market Size by Country/Region (2019-2024) 4.2.1 Global AAV-based Gene Therapy Products Annual Sales by Country/Region (2019-2024) 4.2.2 Global AAV-based Gene Therapy Products Annual Revenue by Country/Region (2019-2024) 4.3 Americas AAV-based Gene Therapy Products Sales Growth 4.4 APAC AAV-based Gene Therapy Products Sales Growth 4.5 Europe AAV-based Gene Therapy Products Sales Growth 4.6 Middle East & Africa AAV-based Gene Therapy Products Sales Growth 5 Americas 5.1 Americas AAV-based Gene Therapy Products Sales by Country 5.1.1 Americas AAV-based Gene Therapy Products Sales by Country (2019-2024) 5.1.2 Americas AAV-based Gene Therapy Products Revenue by Country (2019-2024) 5.2 Americas AAV-based Gene Therapy Products Sales by Type (2019-2024) 5.3 Americas AAV-based Gene Therapy Products Sales by Application (2019-2024) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC AAV-based Gene Therapy Products Sales by Region 6.1.1 APAC AAV-based Gene Therapy Products Sales by Region (2019-2024) 6.1.2 APAC AAV-based Gene Therapy Products Revenue by Region (2019-2024) 6.2 APAC AAV-based Gene Therapy Products Sales by Type (2019-2024) 6.3 APAC AAV-based Gene Therapy Products Sales by Application (2019-2024) 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe AAV-based Gene Therapy Products by Country 7.1.1 Europe AAV-based Gene Therapy Products Sales by Country (2019-2024) 7.1.2 Europe AAV-based Gene Therapy Products Revenue by Country (2019-2024) 7.2 Europe AAV-based Gene Therapy Products Sales by Type (2019-2024) 7.3 Europe AAV-based Gene Therapy Products Sales by Application (2019-2024) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa AAV-based Gene Therapy Products by Country 8.1.1 Middle East & Africa AAV-based Gene Therapy Products Sales by Country (2019-2024) 8.1.2 Middle East & Africa AAV-based Gene Therapy Products Revenue by Country (2019-2024) 8.2 Middle East & Africa AAV-based Gene Therapy Products Sales by Type (2019-2024) 8.3 Middle East & Africa AAV-based Gene Therapy Products Sales by Application (2019-2024) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of AAV-based Gene Therapy Products 10.3 Manufacturing Process Analysis of AAV-based Gene Therapy Products 10.4 Industry Chain Structure of AAV-based Gene Therapy Products 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 AAV-based Gene Therapy Products Distributors 11.3 AAV-based Gene Therapy Products Customer 12 World Forecast Review for AAV-based Gene Therapy Products by Geographic Region 12.1 Global AAV-based Gene Therapy Products Market Size Forecast by Region 12.1.1 Global AAV-based Gene Therapy Products Forecast by Region (2025-2030) 12.1.2 Global AAV-based Gene Therapy Products Annual Revenue Forecast by Region (2025-2030) 12.2 Americas Forecast by Country (2025-2030) 12.3 APAC Forecast by Region (2025-2030) 12.4 Europe Forecast by Country (2025-2030) 12.5 Middle East & Africa Forecast by Country (2025-2030) 12.6 Global AAV-based Gene Therapy Products Forecast by Type (2025-2030) 12.7 Global AAV-based Gene Therapy Products Forecast by Application (2025-2030) 13 Key Players Analysis 13.1 uniQure 13.1.1 uniQure Company Information 13.1.2 uniQure AAV-based Gene Therapy Products Product Portfolios and Specifications 13.1.3 uniQure AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2019-2024) 13.1.4 uniQure Main Business Overview 13.1.5 uniQure Latest Developments 13.2 Spark Therapeutics 13.2.1 Spark Therapeutics Company Information 13.2.2 Spark Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications 13.2.3 Spark Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2019-2024) 13.2.4 Spark Therapeutics Main Business Overview 13.2.5 Spark Therapeutics Latest Developments 13.3 AveXis (Novartis) 13.3.1 AveXis (Novartis) Company Information 13.3.2 AveXis (Novartis) AAV-based Gene Therapy Products Product Portfolios and Specifications 13.3.3 AveXis (Novartis) AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2019-2024) 13.3.4 AveXis (Novartis) Main Business Overview 13.3.5 AveXis (Novartis) Latest Developments 13.4 PTC Therapeutics 13.4.1 PTC Therapeutics Company Information 13.4.2 PTC Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications 13.4.3 PTC Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2019-2024) 13.4.4 PTC Therapeutics Main Business Overview 13.4.5 PTC Therapeutics Latest Developments 13.5 BioMarin 13.5.1 BioMarin Company Information 13.5.2 BioMarin AAV-based Gene Therapy Products Product Portfolios and Specifications 13.5.3 BioMarin AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2019-2024) 13.5.4 BioMarin Main Business Overview 13.5.5 BioMarin Latest Developments 13.6 Sarepta Therapeutics 13.6.1 Sarepta Therapeutics Company Information 13.6.2 Sarepta Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications 13.6.3 Sarepta Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2019-2024) 13.6.4 Sarepta Therapeutics Main Business Overview 13.6.5 Sarepta Therapeutics Latest Developments 13.7 Roche 13.7.1 Roche Company Information 13.7.2 Roche AAV-based Gene Therapy Products Product Portfolios and Specifications 13.7.3 Roche AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2019-2024) 13.7.4 Roche Main Business Overview 13.7.5 Roche Latest Developments 13.8 Pfizer 13.8.1 Pfizer Company Information 13.8.2 Pfizer AAV-based Gene Therapy Products Product Portfolios and Specifications 13.8.3 Pfizer AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2019-2024) 13.8.4 Pfizer Main Business Overview 13.8.5 Pfizer Latest Developments 13.9 CSL Behring 13.9.1 CSL Behring Company Information 13.9.2 CSL Behring AAV-based Gene Therapy Products Product Portfolios and Specifications 13.9.3 CSL Behring AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2019-2024) 13.9.4 CSL Behring Main Business Overview 13.9.5 CSL Behring Latest Developments 13.10 Sangamo Therapeutics 13.10.1 Sangamo Therapeutics Company Information 13.10.2 Sangamo Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications 13.10.3 Sangamo Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2019-2024) 13.10.4 Sangamo Therapeutics Main Business Overview 13.10.5 Sangamo Therapeutics Latest Developments 13.11 Biogen 13.11.1 Biogen Company Information 13.11.2 Biogen AAV-based Gene Therapy Products Product Portfolios and Specifications 13.11.3 Biogen AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2019-2024) 13.11.4 Biogen Main Business Overview 13.11.5 Biogen Latest Developments 13.12 Freeline Therapeutics 13.12.1 Freeline Therapeutics Company Information 13.12.2 Freeline Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications 13.12.3 Freeline Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2019-2024) 13.12.4 Freeline Therapeutics Main Business Overview 13.12.5 Freeline Therapeutics Latest Developments 13.13 Coave Therapeutics 13.13.1 Coave Therapeutics Company Information 13.13.2 Coave Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications 13.13.3 Coave Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2019-2024) 13.13.4 Coave Therapeutics Main Business Overview 13.13.5 Coave Therapeutics Latest Developments 13.14 MeiraGTx 13.14.1 MeiraGTx Company Information 13.14.2 MeiraGTx AAV-based Gene Therapy Products Product Portfolios and Specifications 13.14.3 MeiraGTx AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2019-2024) 13.14.4 MeiraGTx Main Business Overview 13.14.5 MeiraGTx Latest Developments 13.15 RegenxBio 13.15.1 RegenxBio Company Information 13.15.2 RegenxBio AAV-based Gene Therapy Products Product Portfolios and Specifications 13.15.3 RegenxBio AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2019-2024) 13.15.4 RegenxBio Main Business Overview 13.15.5 RegenxBio Latest Developments 13.16 Asklepios Biopharmaceutical 13.16.1 Asklepios Biopharmaceutical Company Information 13.16.2 Asklepios Biopharmaceutical AAV-based Gene Therapy Products Product Portfolios and Specifications 13.16.3 Asklepios Biopharmaceutical AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2019-2024) 13.16.4 Asklepios Biopharmaceutical Main Business Overview 13.16.5 Asklepios Biopharmaceutical Latest Developments 13.17 Audentes Therapeutics 13.17.1 Audentes Therapeutics Company Information 13.17.2 Audentes Therapeutics AAV-based Gene Therapy Products Product Portfolios and Specifications 13.17.3 Audentes Therapeutics AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2019-2024) 13.17.4 Audentes Therapeutics Main Business Overview 13.17.5 Audentes Therapeutics Latest Developments 13.18 Neurophth 13.18.1 Neurophth Company Information 13.18.2 Neurophth AAV-based Gene Therapy Products Product Portfolios and Specifications 13.18.3 Neurophth AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2019-2024) 13.18.4 Neurophth Main Business Overview 13.18.5 Neurophth Latest Developments 13.19 Belief BioMed 13.19.1 Belief BioMed Company Information 13.19.2 Belief BioMed AAV-based Gene Therapy Products Product Portfolios and Specifications 13.19.3 Belief BioMed AAV-based Gene Therapy Products Sales, Revenue, Price and Gross Margin (2019-2024) 13.19.4 Belief BioMed Main Business Overview 13.19.5 Belief BioMed Latest Developments 14 Research Findings and Conclusion